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cant relationships were found between all domains on the
SF-36 with the exception of emotional role limitation and
pain. A regression analysis showed that Hb accounts for
7% of the variability of the fatigue scale of the FACT and
that on this scale a 1 unit rise in Hb equals a rise of 6.27
units. In addition, Hb accounts for an additional 7% of
variability of FACT-An scores and 1 unit rise in Hb
equals a rise of 7.31 units. On average, Hb accounts for
an additional 7% of the variability of the SF-36 scales,
and a 1 unit rise in Hb equals a rise of 7.00 units in SF-36
scales. The PGI showed no relationship with Hb levels.
CONCLUSION: Quality of life as measured by the FACT-
An and the SF-36 is significantly related to Hb levels in
U.K. cancer patients. This indicated that optimization of
patient Hb is likely to increase the quality of life in cancer
patients.
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OBJECTIVE: to estimate the costs and effects of pami-
dronate vs placebo in prevention of bone complications
in metastastic breast cancer in Poland. METHODS: The
model for the Polish health-care context was developed,
based on the use of clinical data from literature and local
data on health-care resource utilization and unit cost.
Only direct medical costs were analyzed. The perspective
of health-care payers and time horizon of 18 months
were taken. In the cost-effectiveness analysis the primary
clinical outcomes for measuring success in the analysis
were the avoided skeletal related events (SRE), which
were defined as pathological fractures, irradiation and
episodes of hypercalcaemia. In the cost-utility analysis
QALY values measured in the analysis were patients
preferences for alternative health outcomes, reported in
the randomized trial. The cost-effectiveness threshold,
calculated on the basis of cost of 1-year haemodialysis
treatment (62 400 PLN, 1 USD  4,5 PLN), was sug-
gested to assess if pamidronate therapy should be adopted.
The one-way sensitivity analysis and threshold analysis
were performed. RESULTS: The costs of avoiding of SRE
for pamidronate vs placebo was 3420 PLN (taking into
consideration lowest costs of treatment of pathological
fractures) or, taking into consideration highest costs of
treatment of pathological fractures, pamidronate treat-
ment was dominant program (129 SRE avoided and 42
546 PLN/100patients/year saved). The cost/QALY gained
was 45 021 PLN or pamidronate was the dominant pro-
gram (9,8 QALY gained and 42 546 PLN/100 patients/
year saved). The results were most sensitive to the costs
of treatment of pathological fractures and number of
SRE avoided. CONCLUSION: Comparing this outcome
with suggested threshold for cost-effectiveness it was
concluded that prophylactic pamidronate therapy for ad-
vanced breast cancer offers substantial benefit at reason-
able cost to the Polish health care system. By assumption
that all pathological fractures would be treated with most
costly methods, pamidronate might be dominant program. 
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Capecitabine is an oral fluoropyrimidine which mimics
continuous 5-FU and is preferentially activated by thymi-
dine phosphorylase to 5-FU within tumor cells. A ran-
domized phase III clinical trial, comparing capecitabine
(n  301, 1250 mg/m2/bid 
 14d, q3 weeks) vs. M-regi-
men (n  301, 5-FU 425 mg/m2; LCV 20 mg/m2 d1-5,
q4 weeks) resulted in a superior response rate (26.6% vs.
17.9%, P  0.013), equivalent progression-free survival
(5.3 vs 4.8 months, HR (hazard ratio) 0.96), equivalent
overall survival (13.2 vs 12.4 months, HR 0.91), and a
superior safety profile for capecitabine. The most remark-
able differences in AEs requiring treatment were lower
rates of infections/sepsis, stomatitis, vomiting, and diar-
rhea and a higher rate of hand-foot syndrome (HFS) for
capecitabine-treated patients. OBJECTIVE: To evaluate
the economic consequences of differences in the AE-pro-
file of capecitabine and M-regimen in colorectal cancer.
METHODS: Patients were recruited from 66 centers in 8
EU-countries, Australia, New Zealand, Russia, Israel and
Taiwan. Data on hospital use, AEs requiring medications
or procedures, and all physician encounters were col-
lected during the clinical trial for all randomized patients
and analyzed. RESULTS: Total days in hospital for: sto-
matitis/mucosal inflammation, HFS, neutropenia, pyr-
exia, infections, diarrhea, nausea and vomiting was re-
duced by 172 hospital days (339 vs. 167, 51%) in the
capecitabine arm. The use of antifungals was reduced by
34% and the usage of 5-HT3-antagonists by 39% in the
capecitabine arm. Although not used frequently, con-
sumption of octreotide and G-CSF was reduced substantially
(100% and 59% respectively) in the capecitabine-treated
group. Overall use of high-cost medication including
cephalosporins and fluoroquinolones was reduced by
56%. Procedures and unscheduled outpatient-visits were
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not economically important. HFS very rarely lead to hospi-
talization (0.7%) and was generally effectively managed by
dose interruption or appropriate dose reduction and patient
education. CONCLUSION: Treatment with capecitabine
avoided 57 hospital days per 100 patients and reduced use
of high-cost medications for AEs by 56% compared to M-
regimen. Reduction in hospitalization observed in this trial
would result in savings in the range of €17,000–€29,000
(depending on country) per 100 patients. AE profiles of dif-
ferent regimens are likely to be important economic factors
in oncology. Stomatitis, infection/sepsis and neutropenia
are of particularly high economic relevance.
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OBJECTIVES: To assess whether different methods of
asking for the willingness to pay (WTP) lead to different
outcomes. METHODS: Sixty people from the general
population were asked for their WTP for a new drug re-
lieving breakthrough cancer pain by a trained interviewer.
All the individuals answered WTP questions posed in
three different randomized ways with the open-card method.
First, they gave their WTP as patients, under certainty of
needing the drug (use or consumption value of the good).
Second, they gave their WTP for a private insurance (op-
tion value) given a probability of 10% of needing the
drug one day. Last, they gave their WTP as contributors
by paying taxes (existence value). The hypothesis of the
research was that the role adopted by the respondent in
the hypothetical situation described for each method in-
fluences results. We expected the WTP for the drug with
the simple method (under certainty) to be lower than the
WTP with the private insurance method and the latter to
be lower than the WTP with the contributor method, as
the different values of the good should be cumulative.
RESULTS: The duration of the interview was between 20
and 25 minutes. Data analysis showed that the different
methods have an influence on the WTP for the drug and
that certain sociodemographic characteristics of the indi-
viduals have an impact on study results. The relevance of
the differences found will be discussed during the presen-
tation. CONCLUSIONS: Different methods of asking for
the WTP lead to differences in outcomes.
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OBJECTIVE: To compare the Quality of Life (QoL) in-
dexes of received two different schemes of chemotherapy
patients in advanced breast cancer. METHODS: Patients
were assigned to chemotherapy. Arm A: standard scheme
CAF (23 pts.), and arm B: included docetaxel scheme
TAD (23 pts.). The instrument for QoL assessment was
FACT-Taxane (Functional Assessment of Cancer Ther-
apy for patients with Taxane toxicity). The questionnaire
consists from 43 questions, 27 of them are general ques-
tions and 16 are questions concerning toxicity reactions
of patients. The patients should answer the questions of
the questionnaire before the treatment, after 3rd and 6th
cycles of chemotherapy. RESULTS: According to re-
ceived data toxicity reactions were more pointed for
TAD scheme than for CAF scheme. The mediana of util-
ity indexes was 57.6 and 51.0 respectively after the 6th
cycle for additional (specific for Taxane) questions. But
the general utility index for arm B was higher than for
arm A, 112 and 109 respectively. CONCLUSION: In
Russia the most limiting factors of docetaxel usage are
related to cost and toxicity issues. In this study we receive
reliable evidence that docetaxel toxicity doesn’t influence
general QoL of the patients. Also in spite of toxicity reac-
tions the QoL of docetaxel treated patients was higher
than standard scheme treated patients. 
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OBJECTIVE: As the US population ages, the increasing
prevalence of cancer is likely to result in higher direct
medical and non-medical costs. While estimates of can-
cer-related direct medical costs exist, very little informa-
tion is available regarding family caregiving costs for eld-
erly cancer patients. Our objective was to determine valid
and generalizable estimates of family caregiving costs for
elderly cancer patients in the US. METHODS: We used
data from the first wave (1993) of the Asset and Health
Dynamics (AHEAD) Study, a nationally representative
longitudinal survey of people aged 70 or older living in
the community. We used a multivariable two-part regres-
sion model to control for differences in health status, so-
cial support, and sociodemographics. The adjusted prob-
ability of receiving family care, the adjusted average
weekly number of caregiving hours, and the average an-
nual caregiving cost per case (assuming an average hourly
wage of $8.30) was estimated for these three groups. RE-
SULTS: Of the 7443 subjects surveyed, 6422 (86%) re-
ported no history of cancer (No Ca), 718 (10%) reported
having a diagnosis of cancer but not receiving treatment
for their cancer in the last year (Ca/No Tx) and 303 (4%)
reported receiving treatment for their cancer in the last
